Prognostic impact of phosphorylated mitogen-activated protein kinase expression in patients with metastatic gastric cancer.

Item

http://www.wikidata.org/entity/Q39523783

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Prognostic impact of phosphory ...... ith metastatic gastric cancer.

@en

Prognostic impact of phosphory ...... ith metastatic gastric cancer.

@nl

type

Item

label

Prognostic impact of phosphory ...... ith metastatic gastric cancer.

@en

Prognostic impact of phosphory ...... ith metastatic gastric cancer.

@nl

prefLabel

Prognostic impact of phosphory ...... ith metastatic gastric cancer.

@en

Prognostic impact of phosphory ...... ith metastatic gastric cancer.

@nl

P1476

Prognostic impact of phosphory ...... ith metastatic gastric cancer.

@en

P2093

Akin Atmaca

http://www.w3.org/2001/XMLSchema#string

Claudia Pauligk

http://www.w3.org/2001/XMLSchema#string

Elke Jäger

http://www.w3.org/2001/XMLSchema#string

Hans-Michael Altmannsberger

http://www.w3.org/2001/XMLSchema#string

Kristina Steinmetz

http://www.w3.org/2001/XMLSchema#string

Salah-Eddin Al-Batran

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.

Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.

Immunohistochemical study on the prognostic value of MIB-1 in gastric carcinoma.

Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer.

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.

Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma.

P304

130-134

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000329063

http://www.w3.org/2001/XMLSchema#string

P433

1-2

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21677458

http://www.w3.org/2001/XMLSchema#string

P921

phosphorylation